Search Results - "Tarabar, Sanela"

Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults by Thompson, Allison, Lamberth, Erik, Severs, Joseph, Scully, Ingrid, Tarabar, Sanela, Ginis, John, Jansen, Kathrin U, Gruber, William C, Scott, Daniel A, Watson, Wendy

“…AbstractIntroductionStreptococcus pneumoniae is a leading cause of bacteremia, bacterial pneumonia, and meningitis, and is associated with substantial…”
Get full text

Evaluation of a Janus kinase 1 inhibitor, PF‐04965842, in healthy subjects: A phase 1, randomized, placebo‐controlled, dose‐escalation study by Peeva, Elena, Hodge, Martin R., Kieras, Elizabeth, Vazquez, Michael L., Goteti, Kosalaram, Tarabar, Sanela G., Alvey, Christine W., Banfield, Christopher

“…Aims To determine the safety, tolerability, pharmacokinetics and pharmacodynamics of the Janus kinase 1‐selective inhibitor, PF‐04965842. Methods This was a…”
Get full text

Safety, Pharmacokinetic, and Pharmacodynamic Evaluation After Single and Multiple Ascending Doses of a Novel Selective Androgen Receptor Modulator in Healthy Subjects by Bhattacharya, Indranil, PhD, Tarabar, Sanela, MD, MPH, Liang, Yali, MS, Pradhan, Vivek, MS, Owens, Jane, PhD, Oemar, Barry, MD

“…Abstract Purpose Tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) properties of single ascending doses (SADs) and multiple ascending doses (MADs)…”
Get full text

Phase I Pharmacokinetic Study of Fixed-Dose Combinations of Ibuprofen and Acetaminophen in Healthy Adult and Adolescent Populations by Tarabar, Sanela, Kelsh, Debra, Vince, Bradley, Leyva, Rina, Song, Dongweon, Matschke, Kyle, Kellstein, David E., Meeves, Suzanne, Cruz-Rivera, Mario

“…Introduction A fixed-dose combination (FDC) of ibuprofen and acetaminophen has been developed that provides greater analgesic efficacy than either agent alone…”
Get full text

Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study by Landis, Megan N., Arya, Mark, Smith, Stacy, Draelos, Zoe, Usdan, Lisa, Tarabar, Sanela, Pradhan, Vivek, Aggarwal, Sudeepta, Banfield, Christopher, Peeva, Elena, Vincent, Michael S., Sikirica, Vanja, Xenakis, Jason, Beebe, Jean S.

“…Background Atopic dermatitis (AD) is a prevalent inflammatory, pruritic skin disease. The Janus kinase (JAK) pathway is a treatment target. Objectives To…”
Get full text

Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study by Tehlirian, Christopher, Singh, Ravi Shankar P., Pradhan, Vivek, Roberts, Erika S., Tarabar, Sanela, Peeva, Elena, Vincent, Michael S., Gale, Jeremy D.

“…Psoriasis treatments lack durable efficacy and have inconvenient administration, highlighting the need for new therapies. To evaluate the efficacy and safety…”
Get full text

Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study by Landis, Megan N, Smith, Stacy R, Berstein, Gabriel, Fetterly, Gerald, Ghosh, Pranab, Feng, Gang, Pradhan, Vivek, Aggarwal, Sudeepta, Banfield, Christopher, Peeva, Elena, Vincent, Michael S, Beebe, Jean S, Tarabar, Sanela

“…Plaque psoriasis (PsO) is an inflammatory skin disease driven, in part, by the activation of Janus kinase (JAK) signalling pathways. To assess the efficacy and…”
Get full text

Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia by Cao, Lishuang, McDonnell, Aoibhinn, Nitzsche, Anja, Alexandrou, Aristos, Saintot, Pierre-Philippe, Loucif, Alexandre J C, Brown, Adam R, Young, Gareth, Mis, Malgorzata, Randall, Andrew, Waxman, Stephen G, Stanley, Philip, Kirby, Simon, Tarabar, Sanela, Gutteridge, Alex, Butt, Richard, McKernan, Ruth M, Whiting, Paul, Ali, Zahid, Bilsland, James, Stevens, Edward B

“…In common with other chronic pain conditions, there is an unmet clinical need in the treatment of inherited erythromelalgia (IEM). TheSCN9Agene encoding the…”
Get more information

Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile by McDonnell, Aoibhinn, Schulman, Betsy, Ali, Zahid, Dib-Hajj, Sulayman D, Brock, Fiona, Cobain, Sonia, Mainka, Tina, Vollert, Jan, Tarabar, Sanela, Waxman, Stephen G

“…Inherited erythromelalgia, the first human pain syndrome linked to voltage-gated sodium channels, is widely regarded as a genetic model of human pain. Because…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study by Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.

“…PF‐05221304 is a liver‐targeted inhibitor of acetyl‐CoA carboxylase, an enzyme that catalyzes the first committed step in de novo lipogenesis (DNL). This…”
Get full text

Safety, Tolerability, and Pharmacokinetics of PF‐06823859, an Anti–Interferon β Monoclonal Antibody: A Randomized, Phase I, Single‐ and Multiple‐Ascending‐Dose Study by Neelakantan, Srividya, Oemar, Barry, Johnson, Kristen, Rath, Natalie, Salganik, Mikhail, Berman, Gabe, Pelletier, Kathleen, Cox, Lori, Page, Karen, Messing, Dean, Tarabar, Sanela

“…This double‐blind, randomized, placebo‐controlled, dose‐ascending, first‐in‐human study (NCT02766621) assessed the safety, tolerability, and pharmacokinetics…”
Get full text

First-in-Human Assessment of the Novel PDE2A PET Radiotracer super( 18)F-PF-05270430 by Naganawa, Mika, Waterhouse, Rikki N, Nabulsi, Nabeel, Lin, Shu-Fei, Labaree, David, Ropchan, Jim, Tarabar, Sanela, DeMartinis, Nicholas, Ogden, Adam, Banerjee, Anindita, Huang, Yiyun, Carson, Richard E

“…This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand 18F-PF-05270430. The primary goals were to determine the appropriate…”
Get full text

First-in-Human Assessment of the Novel PDE2A PET Radiotracer ^sup 18^F-PF-05270430 by Naganawa, Mika, Waterhouse, Rikki N, Nabulsi, Nabeel, Lin, Shu-Fei, Labaree, David, Ropchan, Jim, Tarabar, Sanela, DeMartinis, Nicholas, Ogden, Adam, Banerjee, Anindita, Huang, Yiyun, Carson, Richard E

“…This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand 18F-PF-05270430. The primary goals were to determine the appropriate…”
Get full text

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18 F-PF-05270430 by Naganawa, Mika, Waterhouse, Rikki N., Nabulsi, Nabeel, Lin, Shu-Fei, Labaree, David, Ropchan, Jim, Tarabar, Sanela, DeMartinis, Nicholas, Ogden, Adam, Banerjee, Anindita, Huang, Yiyun, Carson, Richard E.

Get full text

First-in-Human Assessment of the Novel PDE2A PET Radiotracer 18F-PF-05270430 by Naganawa, Mika, Waterhouse, Rikki N, Nabulsi, Nabeel, Lin, Shu-Fei, Labaree, David, Ropchan, Jim, Tarabar, Sanela, DeMartinis, Nicholas, Ogden, Adam, Banerjee, Anindita, Huang, Yiyun, Carson, Richard E

“…This was a first-in-human study of the novel phosphodiesterase-2A (PDE2A) PET ligand (18)F-PF-05270430. The primary goals were to determine the appropriate…”
Get full text

Hearing loss in migrant agricultural workers by Rabinowitz, P, Sircar, K.D, Tarabar, S, Galusha, D, Slade, M.D

“…Background: Farmers have high rates of hearing loss, yet little is known about the hearing status of migrant agricultural workers. We performed a…”
Get full text